Remission in antineutrophil cytoplasmic antibody-associated systemic vasculitis

Chetan Mukhtyar, B. Hellmich, O. Flossmann, R. Luqmani

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

The definition of remission in patients with systemic vasculitis must be distinguished from the term "cure," which implies that patients are well and not requiring ongoing therapy. Remission should be defined using a standardised approach to measuring clinical disease activity, and the definition should be qualified by the duration of the remission and the type of maintenance therapy required to sustain remission. Remission is an important goal of management in the systemic vasculitides and is achievable in most patients. Maintenance of remission is a more difficult target, and evidence from studies of patients with antineutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis indicates that durable, lasting remission is unlikely to occur. Despite good disease control, damage or scarring from disease or its treatment is a common finding and is a separate outcome from remission. Future studies of vasculitis therapies should address the concept of rapid and sustained disease control, so that patients spend most of their time in a state of good health, with minimal damage.
Original languageEnglish
Pages (from-to)93-98
JournalClinical and Experimental Rheumatology
Volume6
Issue number4
Publication statusPublished - Nov 2006

Cite this